Dionysus Accelerates Advancement in Maternal Health with Artificial Intelligence

What You Should Know: 

• Today, the National Institutes of Health (NIH) announced that Dionysus Digital Health, Inc. (Dionysus), a digital health company engaged in the development of precise medical insights using a proprietary digital and epigenetic analysis platform, was selected to move to the next phase of the Rapid Acceleration of Diagnostics  Technology (RADx® Tech) for Maternal Health Challenge. 
• The $8 million cash prize challenge will accelerate the development of technologies to improve maternal health outcomes for those who live in areas lacking access to maternity care. The  CDC recently reported that maternal deaths rose sharply in 2021, with the rates among Black women more than twice as high as those of White women. 
• Dionysus, having passed the Deep Dive Assessment phase, is moving into the Technology  Assessment–and final phase–of the competition, which includes proving their technology works in a real-world test during the remainder of 2023. This last phase will undergo a final review to determine the feasibility of the technology. Winners are expected to be announced in March  2024. 
• The first commercial launch is planned for Q4 2023. 

diagnostics
medical
digital health